Key facts
| Recalling firm | Gilead Sciences, Inc. |
|---|---|
| Manufacturer | Gilead Sciences, Inc. |
| Brand name | VEKLURY |
| Product description | Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 |
| Classification | Class I |
| Recall number | D-0005-2025 |
| Report date | Not disclosed in the FDA record. |
| Status | Terminated |
| Reason for recall | Presence of Particulate Matter: Presence of glass particle. |
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Gilead Sciences, Inc.. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Gilead Sciences, Inc. should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Gilead Sciences, Inc. directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
What this classification means
A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class I, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
Gilead Sciences, Inc.’s FDA history
Argus HQ has recorded 2 total FDA actions tied to Gilead Sciences, Inc.: 0 warning letters, 1 recall, 0 approval records, and 1 Form 483 inspection citation.
Frequently asked questions
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
- Is Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose recalled?
- Yes. FDA lists a Class I recall by Gilead Sciences, Inc. for Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2, reported 20241009, with status "Terminated." FDA recall number: D-0005-2025.
- What is the recall class for Gilead Sciences, Inc.'s recall?
- FDA classified this recall as Class I. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death.
- Why was Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose recalled?
- FDA's recall record states the reason as: Presence of Particulate Matter: Presence of glass particle.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Gilead Sciences, Inc.Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2024). FDA Class I Recall: VEKLURY by Gilead Sciences, Inc.. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/gilead-sciences-d-0005-2025-2024-10-09
"FDA Class I Recall: VEKLURY by Gilead Sciences, Inc.." Argus HQ Research, Digital Empire Holdings LLC, 2024, argushq.ai/recall/gilead-sciences-d-0005-2025-2024-10-09.
Argus HQ Research. "FDA Class I Recall: VEKLURY by Gilead Sciences, Inc.." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/recall/gilead-sciences-d-0005-2025-2024-10-09.
@misc{argushq_argushq_ai_recall_gilead_sciences_d_0005_2025_2024_10_09_2024,
title = {FDA Class I Recall: VEKLURY by Gilead Sciences, Inc.},
author = {{Argus HQ Research}},
year = {2024},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/gilead-sciences-d-0005-2025-2024-10-09},
note = {Accessed: August 27, 2026}
}Source: FDA.gov — Recalls ↗

